IGF-1 LR3
A long-acting insulin-like growth factor analog discussed in physique and performance communities rather than approved peptide medicine.
Also referenced as: Long R3 IGF-1
Also appears in: Growth Hormone
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Muscle Growth. Also surfaces under Growth Hormone for browsing and discovery.
Long R3 IGF-1
No FDA label signal · 0 trials · 15 PubMed results
What IGF-1 LR3 is
IGF-1 LR3 is a modified insulin-like growth factor analog designed for a longer activity profile than native IGF-1. It is usually discussed in physique, recovery, and performance circles rather than in standard FDA-approved therapeutic practice.
Why it matters
This profile belongs in the library because “muscle growth peptides” is one of the most searched peptide buckets online, and readers need at least one clearly labeled example of that category.
Regulatory context
IGF-1 LR3 is not an FDA-approved peptide therapy in the way licensed medicines are. It should be read as a research-market/performance-adjacent compound, not as a mainstream medical treatment.
Practical reading note
This is exactly the kind of profile where category clarity matters: muscle-growth demand is high, but evidence quality, legality, and product quality are all much messier than the marketing usually implies.